Business news for Mon, 24 Dec 2007 & with words administration+million. 3 news.

THE US hotel chain Days Inn is expected to become the first international hotel brand to debut in the Changbai Mountains in northeast China's Jilin Province early next year, the administration committee of the mountain resort has said. By renovating a hotel in Chixi District of the nature reserve for 120 million yuan (US$16 million), the Days Inn hotel will offer 122 European-style rooms. It plans to be operational on January 18.22.

THE China Development Bank and the Tianjin Binhai New Area signed an agreement to set up a venture capital fund to boost high-technology start-ups in the fastest-growing economic zone in north China. The Ministry of Science and Technology Website released yesterday the joint efforts to kick off the first government-backed venture capital worth two billion yuan (US$270 million) with equal contributions from the CDB and the TBNA. Pi Qiansheng, a vice-ministerial official who heads the TBNA administration, said the government funded and operated venture capital would primarily perform as a fund of funds, an investment fund that has a strategy of holding a portfolio of other investment funds rather than investing in tangible projects. Pi said that the fund of funds will choose outstanding domestic and overseas venture capital funds, including private equity funds, to invest. The selected venture capital funds will be asked to prioritize their investment portfolio in high-technology

FISHER & Paykel Healthcare Corp, the New Zealand-based maker of breathing masks to treat sleep disorders, rose to a three-month high in Wellington after the takeover of a rival stoked speculation about more mergers. The Auckland-based company jumped three percent to its highest since September 20, after Respironics Inc, the world's largest manufacturer of the breathing devices, was acquired by Royal Phillips Electronics NV for US$5.2 billion in cash, Bloomberg News reported. Fisher & Paykel has about seven percent of the market for products to treat obstructive sleep apnea, a condition thought to affect as many as 12 million Americans. It is among a handful of companies with US Food & Drug Administration approval to sell OSA devices, along with Respironics and ResMed Inc. "They definitely could be a takeover target because the OSA market is very attractive with its high growth," said Stephen Walker, who manages the equivalent of US$107 million at Walker Capital